Laboratorios Farmaceuticos Rovi, S.A. Share Price Wiener Boerse

Equities

ROVI

ES0157261019

Pharmaceuticals

End-of-day quote Wiener Boerse 23:00:00 25/06/2024 BST 5-day change 1st Jan Change
84.15 EUR +1.02% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. -2.04% +38.63%

Financials

Sales 2024 * 819M 878M 69.46B Sales 2025 * 907M 972M 76.92B Capitalization 4.54B 4.86B 385B
Net income 2024 * 170M 182M 14.41B Net income 2025 * 212M 227M 17.97B EV / Sales 2024 * 5.5 x
Net cash position 2024 * 34.15M 36.58M 2.9B Net cash position 2025 * 147M 158M 12.47B EV / Sales 2025 * 4.84 x
P/E ratio 2024 *
27.2 x
P/E ratio 2025 *
22 x
Employees 1,925
Yield 2024 *
1.3%
Yield 2025 *
1.53%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 day+1.02%
1 week-2.04%
Current month-4.38%
1 month-5.98%
3 months+5.65%
6 months+40.60%
Current year+38.63%
More quotes
1 week
83.30
Extreme 83.3
84.15
1 month
83.30
Extreme 83.3
90.75
Current year
60.95
Extreme 60.95
90.75
1 year
38.38
Extreme 38.38
90.75
3 years
35.64
Extreme 35.64
90.75
5 years
35.64
Extreme 35.64
90.75
10 years
35.64
Extreme 35.64
90.75
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/12/93
Director of Finance/CFO - 31/12/99
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 31/12/94
Director of Finance/CFO - 31/12/99
Chief Executive Officer - 31/12/93
More insiders
Date Price Change
26/06/24 84.15 +1.02%
25/06/24 83.3 -0.24%
24/06/24 83.5 -2.79%
21/06/24 85.9 +1.18%
20/06/24 84.9 +0.24%

End-of-day quote Wiener Boerse, June 25, 2024

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
87.55 EUR
Average target price
94.81 EUR
Spread / Average Target
+8.30%
Consensus

Quarterly revenue - Rate of surprise